General Information of Drug (ID: DMUQ6XH)

Drug Name
AIKO-151 Drug Info
Synonyms Mu-opioid antagonist (oral, opiate dependence), Aiko Biotechnology
Indication
Disease Entry ICD 11 Status REF
Opioid dependence 6C43.2Z Investigative [1]
Cross-matching ID
TTD Drug ID
DMUQ6XH

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Drug(s) Targeting Opioid receptor mu (MOP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Buprenorphine DMPRI8G Opioid dependence 6C43.2Z Approved [2]
Morphine DMRMS0L Advanced cancer 2A00-2F9Z Approved [3]
Hydromorphone DMHP21E Back pain ME84.Z Approved [4]
Tapentadol hydrochloride DMXLSH3 Acute pain MG31 Approved [5]
Fentanyl DM8WAHT Analgesia MB40.8 Approved [6]
Alfentanil DMVO0UB Anaesthesia 9A78.6 Approved [7]
Naloxegol DML0B41 Opioid-induced constipation DB32.1 Approved [8]
Eluxadoline DMYZ0P1 Diarrhea-predominant irritable bowel syndrome DD91.01 Approved [9]
Nalfurafine hcl DMA9DHW Uremic pruritus EC90.10 Approved [10]
Oxycodone DMXLKHV Osteoarthritis FA00-FA05 Approved [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Opioid receptor mu (MOP) TTKWM86 OPRM_HUMAN Antagonist [1]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
2 Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J Neurosci. 2009 Jun 3;29(22):7341-8.
3 Antianalgesia: stereoselective action of dextro-morphine over levo-morphine on glia in the mouse spinal cord.J Pharmacol Exp Ther.2005 Sep;314(3):1101-8.
4 Clinical pipeline report, company report or official report of signaturerx.
5 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
6 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
7 Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain. 2001 Mar;91(1-2):177-87.
8 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
9 Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Biochem Pharmacol.2014 Dec 1;92(3):448-56.
10 Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4.